Provision of Small-Quantity Lipid-Based Nutrient Supplements Increases Plasma Selenium Concentration in Pregnant Women in Malawi: A Secondary Outcome of a Randomized Controlled Trial

Marjorie J Haskell,1,2 Kenneth Maleta,3 Charles D Arnold,1,2 Josh M Jorgensen,1,2 Yue-Mei Fan,4 Ulla Ashorn,4 Andrew Matchado,1 Nagendra K Monangi,5,6 Ge Zhang,5,7,8 Huan Xu,7,8 Elizabeth Belling,7,8 Julio Landero,8 Joanne Chappell,7,8 Louis J Muglia,6,7,10 Mikko Hallman,11 Per Ashorn,4,12 and Kathryn G Dewey1,2

1Institute for Global Nutrition, University of California, Davis, Davis, CA, USA; 2Department of Nutrition, University of California, Davis, Davis, CA, USA; 3Department of Public Health, School of Public Health and Family Medicine, College of Medicine, University of Malawi, Blantyre, Malawi; 4Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; 5Division of Neonatology, Perinatal Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 6Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 7Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA; 8Center for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children’s Hospital Medical Center and March of Dimes Prematurity Research Center Ohio Collaborative, Cincinnati, OH, USA; 9Department of Chemistry, University of Cincinnati, Cincinnati, OH, USA; 10Burroughs Wellcome Fund, Research Triangle Park, NC, USA; 11Medical Research Centre Oulu, PEDEGO Research Unit, University of Oulu, Oulu, Pohjois-Pohjanmaa, Finland; and 12Department of Paediatrics, Tampere University Hospital, Tampere, Finland

ABSTRACT

Background: Pregnant women in Malawi are at risk of selenium deficiency, which can have adverse effects on pregnancy outcomes. Interventions for improving selenium status are needed.

Objectives: To assess the effect of provision of small-quantity lipid-based nutrient supplements (SQ-LNSs) to Malawian women during pregnancy on their plasma selenium concentrations at 36 wk of gestation.

Methods: Pregnant women (≤20 wk of gestation) were randomly assigned to receive daily either: 1) iron and folic acid (IFA); 2) multiple micronutrients (MMN; 130 μg selenium per capsule); or 3) SQ-LNS (130 μg selenium/20 g). Plasma selenium concentrations were measured by inductively coupled plasma mass spectrometry at baseline and after ≥16 wk of intervention (at 36 wk of gestation) and compared by intervention group.

Results: At 36 wk of gestation, median (quartile 1, quartile 3) plasma selenium concentrations (micromoles per liter) were 0.96 (0.73, 1.23), 0.94 (0.78, 1.18), and 1.01 (0.85, 1.28) in the IFA, MMN, and SQ-LNS groups, respectively. Geometric mean (GM) plasma selenium concentration was 5.4% (95% CI: 1.8%, 9.0%) higher in the SQ-LNS group than in the MMN group and tended to be higher than in the IFA group (+4.2%; 95% CI: 1.0%, 7.8%). The prevalence of adjusted plasma selenium concentrations <1 μmol/L was 55.1%, 57.8%, and 47.3% in the IFA, MMN, and SQ-LNS groups, respectively; it was lower in the SQ-LNS group than in the MMN group, OR = 0.44 (95% CI: 0.24, 0.83), and tended to be lower than in the IFA group, OR = 0.54 (95% CI: 0.29, 1.03). There was a significant interaction between baseline plasma selenium concentration and intervention group (P = 0.003). In the lowest tertile of baseline selenium concentrations, GM plasma selenium concentration was higher, and the prevalence of low values was lower in the SQ-LNS group compared with the MMN and IFA groups at 36 wk of gestation (P ≤ 0.007).

Conclusions: Provision of SQ-LNS containing selenium to pregnant women can be an effective strategy for improving their selenium status. This trial was registered at clinicaltrials.gov (identifier: NCT01239693).

Keywords: selenium status, plasma, lipid-based nutrient supplements, pregnancy, Malawi

© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Manuscript received September 29, 2021. Initial review completed January 5, 2022. Revision accepted January 25, 2022. Published online March 7, 2022. Financial support for this work was provided by the Bill & Melinda Gates Foundation (Project Number OPP49817). The source of support had no role in the design or implementation of the study, or in data analysis or interpretation. Author disclosures: The authors report no conflicts of interest. Supplemental Figure 1, Supplemental Tables 1–2, and Supplemental Materials are available from the “Supplementary data” link in the online posting of the article and from the same link in the online table of contents at https://academic.oup.com/cdn/. Abbreviations used: AGP, α1-acid glycoprotein; BRINDA, Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia; CRP, C-reactive protein; GM, geometric mean; GMR, geometric mean ratio; ICP-MS, inductively coupled plasma mass spectrometry; IFA, iron and folic acid; iLiNS, International Lipid-based Nutrient Supplement (Project); MMN, multiple micronutrients; SQ-LNS, small-quantity lipid-based nutrient supplement; UL, tolerable upper intake level.
**Introduction**

Selenium is an essential micronutrient required for reproduction, thyroxine metabolism, DNA synthesis, immune function, and protection from oxidative stress (1). Maternal selenium deficiency has been associated with adverse pregnancy outcomes, including preterm birth and preeclampsia (2–5). Intrauterine infection and an excessive inflammatory response are associated with adverse pregnancy outcomes, and the risk of these conditions can be higher in selenium-deficient women (2). Selenoproteins are involved in the immune response, and selenium-containing enzymes downregulate proinflammatory genes and thus can reduce the adverse effects of inflammation on pregnancy outcomes (2, 6, 7). A recent meta-analysis of 17 cohorts of pregnant women from geographically diverse areas showed that maternal selenium concentrations were significantly associated with preterm birth and gestational duration in some cohorts; however, the association was not generalizable across all the cohorts (8). Significant associations were observed between maternal selenium concentrations and preterm birth in women in the United Kingdom and Tanzania, and the most significant associations were observed in women in Malawi. No associations were observed for the other cohorts (8). In other studies, maternal serum selenium concentrations were also associated with preterm birth in Dutch women in the lowest quartile of serum selenium concentrations (2), and in selenium-deficient HIV-positive Nigerian women (5). In a recent study of Indonesian women, maternal serum selenium concentrations at the time of delivery were not associated with preterm birth; however, selenium concentrations of placenta and cord blood were lower in women with preterm deliveries compared with women who delivered at term (9).

The prevalence of preterm birth is high (18.1%) in Malawi, and inadequate maternal selenium status could be a contributing factor (10). Inadequate selenium intake is endemic in Malawi, where soil and staple crops have low selenium content (11). It is estimated that >80% of the Malawian population is at risk of dietary selenium inadequacy (11). In a nationally representative sample of women of reproductive age in 2015–2016, the prevalence of low plasma selenium concentrations (defined as <1.13 μmol/L) was 62.5% (12). In an earlier smaller study, 83% of pregnant women had low serum selenium concentrations (defined as <1 μmol/L) at 24 wk of gestation (13). Selenium supplementation during pregnancy can be an effective strategy for increasing maternal status. Supplementation with selenium-enriched yeast increased whole blood selenium concentrations in pregnant UK women with low selenium concentrations at enrollment (12–14 wk of gestation) (14). More information is needed on the effect of selenium supplementation during pregnancy on maternal status in populations known to be at risk of deficiency. This information would be useful for planning future studies to assess whether provision of selenium during pregnancy can be effective for preventing preterm birth in areas at high risk of selenium deficiency.

The International Lipid-based Nutrient Supplement (iLiNS) Project tested the efficacy of small-quantity lipid-based nutrient supplements (SQ-LNSs) in several trials, including a randomized, controlled, community-based trial in Malawi (iLiNS/DYAD-M) that was designed to assess the effect of providing SQ-LNSs to mothers during pregnancy and lactation, and to their children from 6 to 18 mo of age, on pregnancy outcomes, child growth and development, and other nutritional and health outcomes (https://ilins.ucdavis.edu/) (15, 16). Because the SQ-LNSs that were provided to women during pregnancy contained selenium, and there was emerging evidence that low selenium status during pregnancy is a risk factor for preterm birth (8), we conducted a subanalysis of the iLiNS/DYAD-M trial to assess whether provision of SQ-LNSs to Malawian women during pregnancy had an effect on their plasma selenium concentrations at 36 wk of gestation.

SQ-LNSs are food supplements that contain peanut paste, vegetable oil, and other ingredients (such as skim milk powder) that are enriched with vitamins and minerals to meet the needs of specific target populations. They were developed to prevent undernutrition in pregnant and lactating women, and in young children in low and middle-income countries (17). SQ-LNSs contain energy, protein, essential fatty acids, and a greater number of micronutrients than multiple micronutrients (MMN), including several macrominerals that are required for growth (17). Recent meta-analyses of SQ-LNSs demonstrated reductions in adverse birth outcomes (18) and in child stunting, wasting, impaired development, anemia, and mortality (19–23), but did not examine maternal selenium status.

**Methods**

**Participants and study design**

The iLiNS/DYAD-M trial was conducted in rural areas of the Mangochi District in southern Malawi; enrollment of pregnant women occurred between February 2011 and August 2012. The primary objective of the trial was to determine whether provision of SQ-LNSs to women during pregnancy and the first 6 mo of lactation, and to children from 6 to 18 mo of age, improves fetal and child growth to a greater extent than consumption of iron and folic acid (IFA) during pregnancy only, or an MMN capsule during pregnancy and the first 6 mo of lactation. The main results of the trial can be found elsewhere (16). Pregnant women who participated in the iLiNS/DYAD-M trial were included in this subanalysis if they had results for plasma selenium concentration at ≤20 wk of gestation and at 36 wk of gestation.

Women who visited the study clinics for antenatal care were eligible for the trial if they were ≤20 wk of gestation (confirmed by ultrasound) and >15 y of age. Exclusion criteria were milk or peanut allergy, chronic disease requiring medical attention, pregnancy complications (moderate to severe edema, hemoglobin <50 g/L, systolic blood pressure >160 mmHg, or diastolic blood pressure >100 mmHg), intent to move away from the area, not a resident of the area, or unwillingness to take the study supplement.

Informed consent was obtained from participants, and the study protocol was approved by the Institutional Review Board of the University of California, Davis, and the Ethics Committees of the College of Medicine, University of Malawi; and the Pirkanmaa Hospital District, Finland.

Pregnant women were randomly assigned to 1 of 3 groups to receive either: 1) IFA (60 mg iron and 400 μg folic acid as a capsule; standard of care); 2) MMN (130 μg selenium plus 17 micronutrients including 20 mg iron as a capsule); or 3) SQ-LNS (20 g sachet that contained 130 μg selenium plus the same 17 micronutrients as the MMN capsule and 4 additional minerals: calcium, phosphorus, potassium, and
Statistical analysis

To maximize our ability to detect a difference in plasma selenium concentration among groups, and potential effect modification by preselected participant characteristics, we measured plasma selenium concentration in all women with paired samples at ≤20 wk of gestation and at 36 wk of gestation (n = 755). A statistical analysis plan was developed and posted prior to analysis, available at https://llins.ucdavis.edu and in the Supplemental Materials. Distributions of outcome variables and key baseline variables were inspected for normality and transformed to natural logs, as necessary. Analyses were performed using SAS version 9.4 (SAS Institute Inc). The covariates included in the ANCOVA models were obtained from the scientific literature and were preselected in our analysis plan. Covariates were included in the model if they were associated with the outcome variable (P < 0.1) to reduce the uncertainty in intervention effect estimates, as recommended by CONSORT guidelines (http://www.consort-statement.org) and best practice guidance (26). Potential covariates for plasma selenium analyses included maternal estimated prepregnancy BMI (27), maternal education, primi-parity, site of enrollment, season at enrollment, baseline household food insecurity score, baseline asset index, baseline plasma selenium concentration, and baseline HIV status. Interactions were examined between group assignment and preselected potential effect modifiers: baseline plasma selenium concentration, baseline HIV status, and baseline inflammation (plasma CRP > 5 mg/L or AGP > 1 g/L). For effect modification testing statistical inference is based on the full model P-interaction rather than analyses conducted separately within subgroups. If a statistically significant interaction (P < 0.1) was found then group means were examined at different levels of the predictor variable, either by category for categorical effect modifiers, or at selected percentile cutoffs for continuous variables to better understand the nature of the effect modification, as recommended by CONSORT guidelines and best practice guidance (26).

The primary statistical analysis was done by complete-case intention-to-treat. The difference in mean plasma selenium concentrations at 36 wk of gestation among the 3 intervention groups was tested with ANOVA (model without covariates) and ANCOVA (model with covariates) and P < 0.05 to indicate statistical significance. Post hoc pairwise comparisons of the intervention groups were done with the Tukey–Kramer test for ANOVA and ANCOVA if the global null hypothesis was rejected with P < 0.05.

The proportion of women with low plasma selenium concentrations at 36 wk of gestation was compared between intervention groups using logistic regression. Tukey–Kramer pairwise comparisons between groups were done in the context of logistic regression if the global null hypothesis was rejected with P < 0.05.

A per protocol analysis was performed that included only participants whose adherence was high, defined as reported consumption of supplements on ≥70% of supplementation days.

Plasma selenium concentration decreases during inflammation because albumin, which is one of the carrier proteins for selenium, is a negative acute-phase protein (28). We used correlation analysis to examine the relation between plasma selenium concentration and plasma concentrations of CRP and AGP, separately, at 36 wk of gestation. If there was a correlation (Spearman correlation P < 0.1) between markers of inflammation and plasma selenium concentration, the method described by the BRINDA (Biomarkers Reflecting Inflammation and

### Collection of blood samples

Nonfasting blood samples were collected from women at ≤20 wk of gestation and at 36 wk of gestation. Time of day and time of consumption of last food other than tea or water were recorded. Blood was centrifuged to obtain plasma (2000 × g for 15 min at ambient temperature), which was aliquoted into cryovials and stored at −80°C for later analysis of the selenium concentration. Plasma samples were shipped in dry ice to the University of California, Davis (Davis, CA) and stored at −80°C, until shipped in dry ice to Cincinnati Children’s Hospital Medical Center (Cincinnati, OH) for measurement of the selenium concentration.

### Laboratory analyses

Plasma selenium concentration was measured by inductively coupled mass spectrometry (ICP-MS, Agilent 7700, Agilent Technologies, Inc) as described previously (8). Baseline and endline plasma samples were analyzed separately. A cutoff value of <1 μmol/L was used to define inadequate selenium status (13).

Plasma concentrations of C-reactive protein (CRP) and α1-acid glycoprotein (AGP) were measured by immunoassay using a COBAS Integra Analyzer (Roche Diagnostics). Cutoff values for plasma markers of inflammation were CRP >5 mg/L and AGP >1 g/L.

magensium). Briefly, a staff member who was not involved with data collection created individual randomization slips, in blocks of 9, and put them in sealed, numbered, opaque envelopes that were stored in numerical order. Eligible women were asked to choose 1 of the top 6 envelopes from the stack; the randomization slip inside the chosen envelope indicated her participant number and group assignment (15). The IFA and MMN capsules were identical in appearance. Fieldworkers delivered a 2-wk supply of participants’ assigned capsule or SQ-LNS to their homes every 14 d. Field workers told women in the IFA and MMN groups to consume 1 capsule/d with a glass of water; women in the SQ-LNS group were told to consume 1 sachet/d of SQ-LNS, mixed with a small amount of any food (16). Adherence was assessed by maternal report and by counting any unused capsules or SQ-LNS sachets from the previous 2-wk period. The field coordinator and field workers who delivered supplements to participants were aware of the participants’ group assignments; all remaining staff were masked to group assignments.

The IFA and MNN capsules were manufactured by DSM Nutritional Products South Africa (Pty) Ltd. The SQ-LNS was produced and packaged by Nutriset S.A.S. Capsules and SQ-LNSs were stored at 20–40°C at the field site. The MMN capsules and 20-g SQ-LNS contained 130 μg selenium in the form of sodium selenite. This amount of selenium was based on twice the amount that is added to the UNIMMAP (United Nations International Multiple Micronutrient Antenatal Preparation) formulation (24). We chose this amount (17) because 130 μg/d resulted in better pregnancy outcomes in women in Guinea-Bissau compared with a daily dose of 65 μg, and because it was known that pregnant women in Malawi are at risk of selenium deficiency (13) and would likely need more than the RDA for selenium for plasma concentrations to increase to adequate levels. Although this amount is ~2.2 times higher than the US RDA for pregnant women (60 μg/d (25)). The nutrient compositions of the IFA, MMN, and SQ-LNS are shown in Supplemental Table 1.

### Effect of SQ-LNS on plasma selenium in pregnancy

Table 1

| Plasma concentration of C-reactive protein (CRP) and α1-acid glycoprotein (AGP) were measured by immunoassay using a COBAS Integra Analyzer (Roche Diagnostics). Cutoff values for plasma markers of inflammation were CRP >5 mg/L and AGP >1 g/L. |
|---|
| Value |
| CRP >5 mg/L |
| AGP >1 g/L |

...
TABLE 1  Characteristics of participants by group at enrollment

| Characteristic                             | IFA       | MMN       | SQ-LNS    |
|-------------------------------------------|-----------|-----------|-----------|
| Number of participants                    | 245       | 261       | 249       |
| BMI, kg/m²                                 | 21.8 ± 2.5| 21.9 ± 3.0| 21.8 ± 2.8|
| Maternal age, y                           | 25.1 ± 5.9| 25.6 ± 6.1| 25.2 ± 6.1|
| Maternal education (completed years at school) | 4.2 ± 3.4 | 4.2 ± 3.3 | 4.2 ± 3.5 |
| Proxy for SES                             | 0.01 ± 1.05| −0.05 ± 0.96| 0.01 ± 1.07|
| Anemia (Hb <100 g/L), %                   | 18.4      | 17.6      | 17.3      |
| Primiparous, %                            | 18.9      | 17.2      | 20.1      |
| Low BMI (≤18.5 kg/m²), %                  | 6.2       | 8.1       | 8.1       |
| Positive HIV test, %                      | 14.5      | 10.8      | 14.1      |
| Positive malaria test (RDT), %           | 20.4      | 24.5      | 22.2      |
| Plasma selenium concentration, μmol/L     | 1.03 ± 0.39| 1.03 ± 0.37| 1.04 ± 0.38|
| Plasma selenium concentration <1 μmol/L, %| 56.1      | 54.5      | 52.3      |
| Plasma CRP concentration >5 mg/L, %       | 38.5      | 37.8      | 48.8      |
| Plasma AGP concentration >1 g/L, %        | 15.2      | 10.8      | 15.3      |
| Inflammation-corrected plasma selenium concentration <1 μmol/L, % | 40.6 | 41.5 | 38.2 |

Values are mean ± SD or percentage. AGP, α1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin; IFA, iron folic acid; MMN, multiple micronutrients; RDT, rapid diagnostic test; SES, socioeconomic status; SQ-LNS, small-quantity lipid-based nutrient supplement.

Nutritional Determinants of Anemia) project was used to correct the selenium results for inflammation (29). Inflammation-corrected and non–inflammation-corrected plasma selenium results are presented.

Before applying the BRINDA correction, we first examined whether the intervention had a statistically significant effect on plasma concentrations of CRP or AGP at 36 wk of gestation.

Results

Participants

A total of 1391 women were enrolled in the iLiNS/DYAD-M trial. Of those, 755 had selenium results for paired plasma samples at ≤20 wk of gestation and 36 wk of gestation and were included in this subanalysis (Supplemental Figure 1). Enrollment characteristics for women that were excluded (n = 636) or included (n = 755) in the selenium subanalysis are shown in Supplemental Table 2. Women who were included differed from those who were excluded in that, on average, they were older (25.3 compared with 24.5 y), completed more years at school (4.2 compared with 3.8 y), and had a lower prevalence of anemia (17.7% compared with 24.4%), a lower prevalence of primiparity (18.7% compared with 25.8%), lower plasma selenium concentration (1.03 compared with 1.08 μmol/L), and a higher prevalence of low inflammation-corrected plasma selenium concentrations (40.1% compared with 33.9%).

Maternal characteristics at enrollment, by intervention group, are shown in Table 1. Mean maternal age was ∼25 y, 17.8% were anemic, 13.1% were HIV-positive, 22.4% tested positive for malaria, 41.7% had elevated plasma CRP concentrations, 13.8% had elevated plasma AGP concentrations, and 40.1% had inflammation-corrected plasma selenium concentrations <1.0 μmol/L.

Inflammation

At 36 wk of gestation, the overall prevalence of elevated CRP and AGP concentrations was 29.5% and 5%, respectively, and the prevalence did not differ by intervention group (P = 0.237 and P = 0.220, respectively).

Plasma selenium concentrations at 36 wk of gestation

Unadjusted geometric mean (GM) plasma selenium concentrations tended to differ by group (P = 0.069; Table 2). After correcting for inflammation and adjusting for baseline plasma selenium concentration, season, and site, the geometric mean ratio (GMR) of plasma selenium concentrations differed significantly by intervention group (P = 0.007); it was higher in the SQ-LNS group than in the MMN group (GMR = 1.05; 95% CI: 1.02, 1.09; Table 2), and it tended to be higher in the SQ-LNS group than in the IFA group (GMR = 1.04; 95% CI: 1.01, 1.08; Table 2).

The prevalence of unadjusted plasma selenium concentrations <1 μmol/L did not differ by group (Table 3). After correcting for inflammation and adjusting for baseline plasma selenium concentration and season, the prevalence of low values differed by group (P = 0.007; Table 3); it was lower in the SQ-LNS group than in the MMN group (OR = 0.44; 95% CI: 0.24, 0.83), and it tended to be lower in the SQ-LNS group than in the IFA group (OR = 0.54; 95% CI: 0.29, 1.03).

There was a significant interaction between baseline plasma selenium concentration and intervention group for GM plasma selenium concentration (P-interaction = 0.005, Figure 1) and the prevalence of low plasma selenium concentrations at 36 wk of gestation (P-interaction = 0.003; Figure 2). The effect of SQ-LNS on plasma selenium concentration was greater in women whose baseline plasma selenium concentration was in the lowest or middle tertiles, and was not evident in those with a baseline selenium concentration in the upper tertile. There were no other interactions between the preselected potential effect modifiers and intervention group.

Per protocol analysis

High adherence was reported by 199 (81.2%) women in the IFA group, 220 (84.3%) in the MMN group, and 213 (85.5%) in the SQ-LNS group. Based on the per protocol analysis, GM plasma selenium concentration differed by group at 36 wk of gestation after correcting for inflammation and adjusting for baseline plasma selenium concentration, season, and site (P < 0.01). GM plasma selenium concentration was higher in the SQ-LNS group compared with the MMN group (GMR = 1.06; 95%
Effect of SQ-LNS on plasma selenium in pregnancy

## TABLE 2

Maternal plasma selenium concentration at 36 wk of gestation by intervention group

| Outcome                          | IFA (n=245) | MMN (n=261) | LNS (n=249) | P value | GMR (95% CI) | Tukey–Kramer P value | GMR (95% CI) | Tukey–Kramer P value | GMR (95% CI) | Tukey–Kramer P value |
|----------------------------------|-------------|-------------|-------------|---------|--------------|---------------------|--------------|---------------------|--------------|---------------------|
| Plasma selenium, μmol/L          | 0.92 (0.88, 0.96) | 0.93 (0.89, 0.97) | 0.98 (0.94, 1.03) | 0.699   | 0.99 (0.96, 1.01) | 0.003               | 1.01 (0.95, 1.07) | 0.093               | 1.01 (0.95, 1.07) | 0.093               |
| Inflammation-corrected plasma selenium, μmol/L | 0.97 (0.95, 1.00) | 0.96 (0.94, 0.99) | 1.02 (0.99, 1.04) | 0.007   | 1.04 (1.01, 1.08) | 0.007               | 0.99 (0.96, 1.02) | 0.003               | 1.04 (1.01, 1.08) | 0.003               |

1. GMR, geometric mean ratio; IFA, iron folic acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrients
2. Unadjusted value.
3. Adjusted for baseline plasma selenium concentration, season, and study site.

At ≤20 wk of gestation the overall prevalence of inflammation-corrected low plasma selenium concentrations (<1 μmol/L) was ~40%. The high prevalence of inadequate status is not surprising given that soil and staple crops have low selenium content in Malawi, and the population is known to be at risk of inadequate selenium intake. Although there was a significant reduction in the prevalence of low selenium concentrations in women in the SQ-LNS group compared with the other groups, the prevalence of low values remained high (~47.3%). We used a cutoff value of <1 μmol/L for inadequate selenium status, which might overestimate the prevalence of selenium deficiency at 36 wk of gestation because of hemodilution that occurs during pregnancy. A decline in plasma selenium concentrations during pregnancy has been observed in European women with low concentrations in early pregnancy. The mean plasma selenium concentration was similar in pregnant Finnish women with adequate status during the first, second, and third trimesters (1.34 ± 0.19 μmol/L, 1.36 ± 0.18 μmol/L, and 1.37 ± 0.19 μmol/L, respectively). Although none of the women had low plasma concentrations during pregnancy their plasma selenium concentrations increased after delivery. In US women, the mean plasma selenium concentration was ~1.9 μmol/L throughout pregnancy. More research is needed to understand the extent to which plasma selenium concentrations are affected by hemodilution, and which cutoff values would be most appropriate in the first, second, and third trimesters of pregnancy.

Nutritional strategies for improving selenium status include supplementation, food fortification, point-of-use fortification, and promotion of production and consumption of foods that are naturally high in selenium content, where possible. In this study, we examined the effect of SQ-LNSs as a point-of-use fortification strategy for improving selenium status during pregnancy. This approach allows for direct targeting of populations that are likely to benefit from the intervention, such as pregnant women, and the amounts of nutrients that are added to the food vehicle can be formulated to meet the specific needs of the pregnant woman.
TABLE 3  Prevalence of low maternal plasma selenium concentration at 36 wk of gestation by intervention group

| Outcome                              | Comparison between LNS and IFA group | Comparison between MMN and IFA group | Comparison between LNS and MMN group |
|--------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                      | Prevalence                          | OR (95% CI)                         | OR (95% CI)                         | OR (95% CI)                         |
|                                      |                                     | Tukey–Kramer P value                | Tukey–Kramer P value                | Tukey–Kramer P value                |
| Plasma selenium <1.0 μmol/L,^2%       |                                     |                                     |                                     |                                     |
| IFA (n = 245)                        | 60.0                                | 0.82 (0.53, 1.25)                   | 1.13 (0.73, 1.73)                   | 0.72 (0.47, 1.11)                   |
| MMN (n = 261)                        | 62.8                                | 0.503                               | 0.790                               | 0.173                               |
| LNS (n = 249)                        | 55.0                                | 0.007                               | 0.063                               | 0.006                               |
| Inflammation-corrected plasma        |                                     |                                     |                                     |                                     |
| plasma selenium <1.0 μmol/L,^3%       |                                     |                                     |                                     |                                     |
| IFA (n = 245)                        | 55.1                                | 0.55 (0.29, 1.03)                   | 1.23 (0.66, 2.30)                   | 0.44 (0.24, 0.83)                   |
| MMN (n = 261)                        | 57.8                                |                                      | 0.708                               |                                     |
| LNS (n = 249)                        | 47.3                                |                                      |                                     |                                     |

^1IFA, iron folic acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrients.
^2Unadjusted values.
^3Adjusted for baseline selenium concentration and season.

1IFA, iron folic acid; LNS, lipid-based nutrient supplement; MMN, multiple micronutrients.

In the United Kingdom, selenium status increased in pregnant women who were supplemented with selenium-enriched yeast (60 μg/d in the form of selenomethionine) from ∼12 wk to 35 wk of gestation: in women in the lowest tertile of baseline selenium status, median whole blood selenium concentration at 35 wk of gestation was 1.87 μmol/L compared with 1.16 μmol/L in the control group (2). In contrast to our findings, provision of SQ-LNS containing sodium selenite to lactating HIV-positive Malawian women, beginning at 2 or 6 wk postpartum and continuing until 24 wk postpartum, had no effect on their plasma or breastmilk selenium concentrations at 24 wk postpartum in a randomized controlled trial (38). The lower dose and/or differences in absorption/retention or utilization of selenium in the form of sodium selenite, compared with selenium in the form of selenomethionine, might account for the lack of response in the MMN group. In the MMN group, plasma selenium concentrations in women who were supplemented with sodium selenite increased, but not in response to supplementation with selenium from food sources (36). Selenium from food is enhanced when consumed with vitamins A, E, and D, and/or low-molecular-weight proteins containing methionine (39). SQ-LNS provides selenium in food matrix that contains vitamins and proteins, whereas MMN provides selenium mixed with other micronutrients. This might explain why plasma selenium concentrations in response to SQ-LNS supplementation were higher than to MMN supplementation, whereas MMN supplementation was not able to detect differences in selenium status. Our results suggest that provision of SQ-LNS during pregnancy can be an effective strategy for improving selenium status in women at risk of deficiency. Our study has several strengths, including a randomized controlled trial design, adequate sample size, and detection of differences in selenium status at 24 wk postpartum. In the United Kingdom, selenium status increased in pregnant women who were supplemented with selenium-enriched yeast (60 μg/d in the form of selenomethionine) from ∼12 wk to 35 wk of gestation: in women in the lowest tertile of baseline selenium status, median whole blood selenium concentration at 35 wk of gestation was 1.87 μmol/L compared with 1.16 μmol/L in the control group (2). In contrast to our findings, provision of SQ-LNS containing sodium selenite to lactating HIV-positive Malawian women, beginning at 2 or 6 wk postpartum and continuing until 24 wk postpartum, had no effect on their plasma or breastmilk selenium concentrations at 24 wk postpartum in a randomized controlled trial (38). The lower dose and/or differences in absorption/retention or utilization of selenium in the form of sodium selenite, compared with selenium in the form of selenomethionine, might account for the lack of response in the MMN group. In the MMN group, plasma selenium concentrations in women who were supplemented with sodium selenite increased, but not in response to supplementation with selenium from food sources (36). Selenium from food is enhanced when consumed with vitamins A, E, and D, and/or low-molecular-weight proteins containing methionine (39). SQ-LNS provides selenium in food matrix that contains vitamins and proteins, whereas MMN provides selenium mixed with other micronutrients. This might explain why plasma selenium concentrations in response to SQ-LNS supplementation were higher than to MMN supplementation, whereas MMN supplementation was not able to detect differences in selenium status. Our results suggest that provision of SQ-LNS during pregnancy can be an effective strategy for improving selenium status in women at risk of deficiency. Our study has several strengths, including a randomized controlled trial design, adequate sample size, and detection of differences in selenium status at 24 wk postpartum.

Our results suggest that provision of SQ-LNS during pregnancy can be an effective strategy for improving selenium status in women at risk of deficiency. Our study has several strengths, including a randomized controlled trial design, adequate sample size, and detection of differences in selenium status at 24 wk postpartum.
Effect of SQ-LNS on plasma selenium in pregnancy

FIGURE 1  Geometric mean inflammation-corrected selenium concentration at 36 wk of gestation stratified by tertile of baseline plasma selenium concentration. Results are corrected for inflammation and adjusted for baseline plasma selenium concentration; \( P \)-interaction = 0.005. GM plasma selenium concentration was higher in the SQ-LNS group compared with the MMN and IFA groups in women in the lowest tertile (GMR = 1.14; 95% CI: 1.07, 1.23; and GMR = 1.15; 95% CI: 1.07, 1.24). In the middle tertile, it was higher in the SQ-LNS group than in the MMN group (GMR = 1.09; 95% CI: 1.01, 1.17) and tended to be higher than in the IFA group (GMR = 1.07; 95% CI: 0.99, 1.15). The GM values did not differ by group in the upper tertile. GM, geometric mean; GMR, geometric mean ratio; IFA, iron folic acid; MMN, multiple micronutrients; SQ-LNS, small-quantity lipid-based nutrient supplement.

at enrollment between women who were excluded compared with included in the plasma selenium subanalysis: the latter were slightly older, completed more years at school, and had a lower prevalence of anemia and primiparity and lower plasma selenium concentrations. Because women who were included in the analysis had a higher prevalence of low inflammation-corrected plasma selenium concentrations (40.1% compared with 33.9%) at enrollment, compared with those who were excluded, they might have been more responsive to the intervention. However, more than one-third of the excluded women also had low selenium status, indicating that it was common in the full study group. Other limitations include lack of data on dietary intake of selenium, the use of a single marker of selenium status, and uncertainty regarding an appropriate cutoff for plasma selenium concentration in late pregnancy. The amount of selenium provided in our study (130 \( \mu \)g/d) is \( \sim \)2.2 times the North American RDA for pregnant women but is much lower than the UL of 400 \( \mu \)g/d. Although our study population responded to SQ-LNS

FIGURE 2  Prevalence of plasma selenium concentrations <1 \( \mu \)mol/L stratified by tertile of baseline plasma selenium concentration. Results are corrected for inflammation and adjusted for baseline plasma selenium concentration; \( P \)-interaction = 0.003. Prevalence of low plasma selenium concentration was lower in the SQ-LNS group than in the MMN and IFA groups in the lowest tertile (OR = 0.39; 95% CI: 0.15, 1.00; and OR = 0.28; 95% CI: 0.10, 0.81). In the middle tertile, it was lower in the SQ-LNS group than in the MMN group (OR = 0.38; 95% CI: 0.20, 0.71), but did not differ from that of the IFA group. There were no differences by group in the upper tertile. IFA, iron folic acid; MMN, multiple micronutrients; SQ-LNS, small-quantity lipid-based nutrient supplement.
References

References made available upon request pending application to the authors.

Acknowledgments

The authors’ responsibilities were as follows—KGD, PA, KM, UA: designed the research; MJH, PA, UA, JMJ, Y-MF, MH, KM: conducted the research; CDA: conducted statistical analyses; NKM, JC, EZ, RJM: supervised ICP-MS analyses; EB, NKM, HX, GZ, JL: performed the selenium measurements and analytics; MJH: wrote the paper; MJH, KGD: had primary responsibility for final content; and all authors: read and approved the final manuscript.

Data Availability

Data described in the manuscript, codebook, and analytic code will be made available upon request pending application to the authors.

References

1. Duntas LH. Selenium and at-risk pregnancy: challenges and controversies. Thyroid Res 2020;13(1):16.
2. Rayman MP, Wijnen H, Vader H, Kooistra L, Pop V. Maternal selenium status during early gestation and risk for preterm birth. Can Med Assoc J 2011;183(5):549–55.
3. Yıldırım E, Derici MK, Demir E, Apaydin H, Koçak Ö, Kan Ö, Gökerm U. Is the concentration of cadmium, lead, mercury, and selenium related to preterm birth? Biol Trace Elem Res 2019;191(2):306–12.
4. Xu M, Guo D, Gu H, Zhang L, Lv S. Selenium and preeclampsia: a systematic review and meta-analysis. Biol Trace Elem Res 2016;171(2):283–92.
5. Okunade KS, Olowoselu OF, Osanyin GE, John-Obabode S, Akannmu SA, Anorlu RI. Selenium deficiency and pregnancy outcome in pregnant women with HIV in Lagos, Nigeria. Int J Gynaecol Obstet 2018;142(2):207–13.
6. Vunda H, Belda BJ, Arner RJ, Channa Reddy C, Vanden Heuvel JP, Sandeep Prabhu K. Selenium attenuates pro-inflammatory gene expression in macrophages. Mol Nutr Food Res 2008;52(11):1316–23.
7. MosesEK,JohnsonMP,TimmelardL,ForssmoS,CurranJE,Achlam LB, ScalethJC, Brenchneke SP, Blangero J, Austgulen R. Genetic association of preeclampsia to the inflammatory response gene SEPS1. Am J Obstet Gynecol 2008;198(3):336.e1–5.
8. Monangi NK, Xu H, Khanam R, Khan W, Deb S, Pervin J, Price JT, INTERBIO-21st Study Consortium, Kennedy SH, Mahmud AA, et al. Association of maternal prenatal selenium concentration and preterm birth: a multi-country meta-analysis. BMJ Glob Health 2021;6(9):e005856.
9. Irwinda R, Wibowo N, Purti AS. The concentration of micronutrients and heavy metals in maternal serum, placenta, and cord blood: a cross-sectional study in preterm birth. J Preg 2019;2019:5062365.
10. Chidzuga G, Choko AT, Maluwa A, Huber S, Oldland J. Maternal serum concentrations of selenium, copper, and zinc during pregnancy are associated with risk of spontaneous preterm birth: a case-control study from Malawi. J Preg 2020;2020:9435972.
11. Hurst R, Siyame EW, Young SD, Chilimba AD, Joy EJ, Black CR, Ander EL, Watts MJ, Chilimba B, Gondwe J, et al. Soil-type influences human selenium status and underlies widespread selenium deficiency risks in Malawi. Sci Rep 2013;3(1):1425.
12. Phiri FP, Ander EL, Bailey EH, Chilimba B, Chilimba ADC, Gondwe J, Joy EJM, Kalimbira AA, Kumssa DB, Lark RM, et al. The risk of selenium deficiency in Malawi is large and varies over multiple spatial scales. Sci Rep 2019;9(1):6566.
13. Gibson RS, Bailey KB, Ampong Romano AB, Thomson CD. Plasma selenium concentrations in pregnant women in two countries with contrasting soil selenium levels. J Trace Elem Med Biol 2011; 25(4):230–5.
14. Rayman MP, Searle E, Kelly L, Johnsen S, Bodman-Smith K, Bath SC, Mao J, Redman CW. Effect of selenium on markers of risk of pre-eclampsia in UK pregnant women: a randomised, controlled pilot trial. Br J Nutr 2014;112(1):99–111.
15. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Harjunnaa U, Larthey A, Nikhoma M, Phiri N, Phuka J, et al. The impact of lipid-based nutrient supplement provision to pregnant women on newborn size in rural Malawi: a randomized controlled trial. Am J Clin Nutr 2015;101(2):387–97.
16. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Gondwe A, Harjunnnua U, Larthe A, Phiri N, Phiri TE, et al. Supplementation of maternal diets during pregnancy and for 6 months postpartum and infant diets thereafter with small-quantity lipid-based nutrient supplements does not promote child growth by 18 months of age in rural Malawi: a randomized controlled trial. J Nutr 2015;145(6):1345–53.
17. Arimond M, Zeilani M, Jungjohann S, Brown K, Ashorn P, Allen L, Dewey K. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-based Nutrient Supplements (iLiNS) Project. Matern Child Nutr 2015;11:31–61.
18. Das JK, Hoodhoyi Z, Salam RA, Bhutta AZ, Valenzuela-Rubio NG, Weise Prinzo Z, Bhutta ZA. Lipid-based nutrient supplements for maternal, infant and infant developmental outcomes. Cochrane Database Syst Rev 2018;8:CD012610.
19. Das JK, Salam RA, Hadi YB, Sadiq Sheikh S, Bhutta AZ, Weise Prinzo Z, Bhutta ZA. Preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. Cochrane Database Syst Rev 2019;5:CD012611.
20. Dewey KG, Wessells KR, Arnold CD, Prado EL, Abbeddou S, Adu-Afarwuah S, Ali H, Arnold BF, Ashorn P, Ashorn U, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr 2021;114(Suppl 1):155–425.
21. Prado EL, Arnold CD, Wessells KR, Stewart CP, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn U, Beccue E, et al. Small-quantity lipid-based nutrient supplements for children age 6–24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. Am J Clin Nutr 2021;114(Suppl 1):43S–67S.
22. Wessells KR, Arnold CD, Stewart CP, Prado EL, Abbeddou S, Adu-Afarwuah S, Arnold BF, Ashorn P, Ashorn U, Beccue E, et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. Am J Clin Nutr 2021;114(Suppl 1):685–945.
23. Stewart CP, Wessells KR, Arnold CD, Huybregts L, Ashorn P, Beccue E, Humphrey JH, Dewey KG. Lipid-based nutrient supplements and all-cause mortality in children 6–24 months of age: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2020;111:207–18.
24. Margetts BM, Fall CH, Ronsmans C, Allen LH, Fisher DJ. Multiple micronutrient supplementation during pregnancy in low-income countries: decreasing risk of preterm birth? Biol Trace Elem Res 2019;191(2):306–12.
Effect of SQ-LNS on plasma selenium in pregnancy

review of methods and characteristics of studies included in the meta-analyses. Food Nutr Bull 2009;30(4 Suppl 4):S517–26.

25. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids. Washington (DC): National Academies Press; 2000.

26. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21(19):2917–30.

27. Adu-Afarwuah S, Larney A, Okronipa H, Ashorn P, Peerson JM, Arimond M, Ashorn U, Zeilani M, Vosti S, Dewey KG. Small-quantity, lipid-based nutrient supplements provided to women during pregnancy and 6 mo postpartum and to their infants from 6 mo of age increase the mean attained length of 18-mo-old children in semi-urban Ghana: a randomized controlled trial. Am J Clin Nutr 2016;104(3):797–808.

28. Dehi IR, Yamazaki C, Kameo S, Kobayashi K, Nakazawa M, Shinya Y, Sato N, Wada N, Shirakura K, Koyama H. Acute phase response of selenium status and glutathione peroxidase activity in blood plasma before and after total knee arthroplasty surgery. Biol Trace Elem Res 2011;144(1–3):388–95.

29. Namaste SM, Rohner F, Huang J, Bhushan NL, Flores-Ayala R, Kupka R, Mei Z, Rawat R, Williams AM, Raiten DJ, et al. Adjusting ferritin concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) Project. Am J Clin Nutr 2017;106:596S–71S.

30. Chilimba AD, Young SD, Black CR, Rogerson KB, Ander EL, Watts MJ, Lammel J, Brodley MR. Maize grain and soil surveys reveal suboptimal dietary selenium intake is widespread in Malawi. Sci Rep 2011;1(1):72.

31. Zachara B. Selenium in pregnant women: mini-review. J Nutr Food Sci 2016;6:492.

32. Zachara BA, Wardak C, Didkowski W, Maciag A, Marchaluk E. Changes in blood selenium and glutathione concentrations and glutathione peroxidase activity in human pregnancy. Gynecol Obset Invest 1993;35(1):12–17.

33. Uotila J, Tuimala R, Aarnio T, Pyykko K, Ahotupa M. Lipid peroxidation products, selenium-dependent glutathione peroxidase and vitamin E in normal pregnancy. Eur J Obset Gynecol Reprod Biol 1991;42(2):95–100.

34. Kundu N, Parke P, Palmer IS, Olson O, Petersen LP. Distribution of serum selenium, copper, and zinc in normal human pregnancy. Arch Environ Health 1985;40(5):268–73.

35. Fairweather-Tait SJ, Collings R, Hurst R. Selenium bioavailability: current knowledge and future research requirements. Am J Clin Nutr 2010;91(5):1484S–91S.

36. Kieliszek M. Selenium: fascinating microelement, properties and sources in food. Molecules 2019;24(7):1298.

37. Hill KE, Xia Y, Akesson B, Boeglin ME, Burk RF. Selenoprotein P concentration in plasma is an index of selenium status in selenium-deficient and selenium-supplemented Chinese subjects. J Nutr 1996;126(1):138–45.

38. Flax VL, Bentley ME, Combs GF, Chasela CS, Kayira D, Tegha G, Kamwendo D, Daza EJ, Fokar A, Kourtis AP, et al. Plasma and breast-milk selenium in HIV-infected Malawian mothers are positively associated with infant selenium status but are not associated with maternal supplementation: results of the Breastfeeding, Antiretrovirals, and Nutrition study. Am J Clin Nutr 2014;99(4):950–6.